TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04331392

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spatial Navigation Intervention
Description: The 16-week intervention is completed daily, 5 days/week, remotely from home on a designated study website. Each week participants learn a new city through navigation tasks which increase in difficulty day-to-day and have a total of 4 levels of difficulty, with the goal of being able to independently navigate the city by the end of the week via Google Street View. Participants complete end-of-day multiple-choice tasks, testing what they learned with 3 types of allocentric questions: 1) predicting the next street/landmark, 2) distance judgement and 3) vector mapping. Participants also complete a map placement task, which involves reporting the locations of all studied landmarks/streets.~Participants are presented with auditory rewards in the forms of short audio clips about landmarks, written encouragement in the form pop-ups (e.g., Good work, keep it up!), and coffee card rewards based on adherence to the intervention (e.g.,$5 bi-weekly if 100% of intervention is completed).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Videos
Description: The 16-week active control, remote video intervention is completed daily, 5 days a week by participants on a designated website. Participants placed in the active control group are trained on educational topics by watching videos of Ted Talks, to control for the effects of generalized environmental enrichment of the same dose as targeted navigation training. For each day of training, participants are asked to select between an option of 2 possible videos, watching a total of three videos per day. To ensure compliance and sufficient attention to the videos, at the end of each video, participants are asked to rate 5 aspects of the content (relevance, interest, comprehensibility, complexity, informative), and speaker (persuasiveness, quality of delivery, facial expression, convincingness, captivation), on a scale of 1 (lowest) to 5 (highest). Additionally, as with remote navigation participants, they are given written and monetary rewards.
Study: NCT00550355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD 0360324
Description: 3 doses of PD 0360324 (Dose level 3) administered over 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered over 12 weeks
Study: NCT04464174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Study: NCT03784612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App-technology for healthy eating habits
Description: Access to smartphone-app, including a 12 week healthy eating program. A new theme on healthy dietary habits is presented each week.
Study: NCT01909752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DRibble vaccine
Description: DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV vaccine
Description: Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
Study: NCT01860690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 50 mg / meter squer Intramuscular (IM) MTX.
Study: NCT04464174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
Study: NCT04086056

Intervention type: OTHER
Intervention: NIRS monitoring
Description: Regional cerebral oxygen saturation (rScO₂) will be collected by NIRS monitoring before anesthesia induction, during surgery and after extubation, in children with craniosynostosis.
Study: NCT01999920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilazodone
Description: 10mg to 40mg per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One to two pills per day for 12 weeks
Study: NCT04731805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moving On After Breast Cancer
Description: Patient education intervention that is evidence-based, physical therapy, patient \& family centered through the use of face to face instruction, a booklet, and therapeutic exercise DVD. The education materials are designed to deliver information on short term, long term, and late physical and functional effects of breast cancer treatment and given to breast cancer survivors before beginning cancer treatment. The education materials are designed to be used before, during, and after breast cancer treatment.
Study: NCT03067727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: The DVI contains 10 mg Dinoprostone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo product is identical with the active product except that it does not contain Dinoprostone.
Study: NCT02894021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: classic closure
Description: mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: padding
Description: areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
Study: NCT03809845

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface electromyography
Description: High-density surface electromyography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface electromyography
Description: High-density surface electromyography
Study: NCT00930358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEOPA
Description: anaesthetic gaz inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anaesthesia
Description: Anaesthetic intravenous route
Study: NCT03221257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone (PFD)
Description: Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Plac)
Description: Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil (MMF)
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate Mofetil (MMF)
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Study: NCT00122148

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Feedback on provision of care
Study: NCT03428009

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Study interventions are minimal risk.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Study interventions are minimal risk.
Study: NCT03781518

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ridge splitting in group and khoury shell technique in the other group
Description: Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ridge splitting in group and khoury shell technique in the other group
Description: Mandibular ridge splitting with complete separation of the buccal cortical plate for horizontal augmentation of atrophic posterior mandible in one group and the other group will receive khoury shell technique by taking bone block from the ramus
Study: NCT04051892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FixNip™ NRI
Description: The FixNip™ NRI is an implantable hypodermic, silicone implant specially designed for nipple areola definition
Study: NCT03119103

Intervention type: DEVICE
Group type: OTHER
Intervention: Functional Bed Sheet
Description: All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
Study: NCT04015661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: induction chemotherapy with nab-paclitaxel and nedaplatin followed by concurrent chemoradiotherapy
Study: NCT00851175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: 7 day treatment with rosuvastatin 1dd 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: 7 day treatment with rosuvastatin 1dd 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
Study: NCT01379365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryo-Touch III
Description: Percutaneous treatment with the device
Study: NCT00851175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine
Description: intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
Study: NCT02957461

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.

Intervention type: DEVICE
Intervention: BrainScope Ahead 200iD
Description: The BrainScope Battery evaluation will consist of 4 tests to aid in the assessment of concussion: History, Physical, signs and symptoms (SAC, SCAT3), Electrophysiological Function; Neurocognitive Performance Assessment and Ocular Motor assessment. BrainScope Ahead 200iD device will be used to perform EEG.
Study: NCT01620606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy & Social Learning
Description: Cognitive Behavioral Therapy \& Social Learning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy & Social Learning
Description: Cognitive Behavioral Therapy \& Social Learning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Support
Description: Education about the GI system, nutrition and food safety
Study: NCT04596852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch
Description: Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Assessment of the reliability of a protocol characterizing intersegmental hyper-resistance to passive stretch
Description: Passive solicitations of the main joints of the lower limb, of healthy children and children with cerebral palsy, are realized by two evaluators with a handheld dynamometer.~Repeated measures are performed to assess intra and inter-reliability.
Study: NCT01548456

Intervention type: PROCEDURE
Intervention: Intramedullary Nailing
Description: Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique

Intervention type: PROCEDURE
Intervention: Open Reduction Internal Fixation
Description: Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
Study: NCT04605471

Intervention type: DRUG
Intervention: Iopromide(Ultravist, BAY86-4877)
Description: The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.

Intervention type: DRUG
Intervention: Iopromide(Ultravist, BAY86-4877)
Description: The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.

Intervention type: DRUG
Intervention: Iopromide(Ultravist, BAY86-4877)
Description: The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.

Intervention type: DRUG
Intervention: Iopromide(Ultravist, BAY86-4877)
Description: The study will be conducted by using pooled data of four company sponsored non-interventional studies with iopromide.
Study: NCT03742245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: HDAC inhibitor
Study: NCT03159611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral. 10 drops daily, at the same time in the morning, 15 minutes before feeding.
Study: NCT00162981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam Low Dose
Description: 5 to 10 mg/day with doses in the morning and at bedtime; orally
Study: NCT02058368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5mg capsules
Description: Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride placebo capsules
Description: Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride placebo capsules
Description: Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2mg tablets
Description: Commercially available tamsulosin 0.2mg tablets will be supplied.
Study: NCT00162981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam High Dose
Description: 5 to 40 mg/day with doses in the morning and at bedtime; orally
Study: NCT00505713

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Rexin-G
Description: Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
Study: NCT01408290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-3511
Description: One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-6011
Description: One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with FAB-9011
Description: One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
Study: NCT03198611

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Usual echocardiographic studies in patients suffering septic shock

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Usual echocardiographic studies in patients suffering septic shock

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Usual echocardiographic studies in patients suffering septic shock

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Usual echocardiographic studies in patients suffering septic shock
Study: NCT01347203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPOC-4088
Description: A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
Study: NCT02284997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGDRx® EyeBag
Description: Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
Study: NCT02460198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study: NCT04645212

Intervention type: BIOLOGICAL
Intervention: ADVM-022
Description: Long term follow-up of subjects that received ADVM-022
Study: NCT03449303

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EOI
Description: Topically-applied oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topically-applied oil
Study: NCT00993213

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care with Liposuction
Description: Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard of Care without Liposuction
Description: Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.